The short version of albumin binding fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-07 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Stability depends strongly on physical form. The dry powder is generally regarded as stable for extended periods when held at or below minus twenty degrees Celsius in a sealed, desiccated container. In solution, degradation pathways include deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation. Reaction rates for these pathways rise with temperature. Repeated freezing and thawing of solutions promotes aggregation, and light exposure can accelerate some oxidative changes. Buffer composition and pH influence which pathway dominates at a given temperature.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Degradation pathways for tirzepatide include deamidation, oxidation, and aggregation, which are common for therapeutic peptides. These processes can be monitored by size-exclusion chromatography (SEC) for aggregates and ion-exchange chromatography for charge variants. Forced degradation studies under acidic, basic, oxidative, and thermal stress help identify potential impurities. The exact stability profile depends on formulation, concentration, and container-closure system.
Analytical characterization of tirzepatide typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) for purity assessment and peptide mapping. Mass spectrometry, often coupled with electrospray ionization, confirms molecular weight and sequence integrity. Amino acid analysis and capillary electrophoresis may also be used to detect impurities or degradation products. These methods are essential for batch release and stability studies.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
The gate formed by the α subunits prevents peptides longer than about four residues from entering the interior of the 20S particle. The ATP molecules bound before the initial recognition step are hydrolyzed before translocation. While energy is needed for substrate unfolding, it is not required for translocation. The assembled 26S proteasome can degrade unfolded proteins in the presence of a non-hydrolyzable ATP analog, but cannot degrade folded proteins, indicating that energy from ATP hydrolysis is used for substrate unfolding. Passage of the unfolded substrate through the opened gate occurs via facilitated diffusion if the 19S cap is in the ATP-bound state. The mechanism for unfolding of globular proteins is necessarily general, but somewhat dependent on the amino acid sequence. Long sequences of alternating glycine and alanine have been shown to inhibit substrate unfolding, decreasing the efficiency of proteasomal degradation; this results in the release of partially degraded byproducts, possibly due to the decoupling of the ATP hydrolysis and unfolding steps. Such glycine-alanine repeats are also found in nature, for example in silk fibroin; in particular, certain Epstein–Barr virus gene products bearing this sequence can stall the proteasome, helping the virus propagate by preventing antigen presentation on the major histocompatibility complex.
The human penis is thicker than that of any other primate, both in absolute terms and relative to the rest of the body. Early research, based on inaccurate measurements, concluded that the human penis was also longer. In fact, the penis of the common chimpanzee is no shorter than in humans, averaging 14.4 cm (5.7 inches), and some other primates have comparable penis sizes relative to their body weight. The evolutionary reasons for the increased thickness have not been established. One explanation is that thicker penises are an adaptation to a corresponding increase in vaginal size. The vaginal canal is believed to have expanded in humans to accommodate the larger size of a newborn's skull. Women may then have sexually selected men with penises large enough to fit their vagina, to provide sexual stimulation and ensure ejaculation. Other evolutionary hypotheses to explain humans' relatively large penis length and girth include a sperm competition hypothesis and a mate competition hypothesis. The sperm competition hypothesis does not have much support as in other mammals where sperm competition is present, larger testes evolve, not larger penises. The mate competition hypothesis involves the prediction that a human with a larger penis would be able to displace the sperm of another. Studies have found that larger penises do not displace other sperm more effectively than smaller penises, but rather longer penises may ejaculate sperm inside the vagina in places that would be harder for a following penis to displace.
=== Officers === To gain a commission, Potential Officers have to pass the two stages of the Army Officer Selection Board (AOSB) and then successfully complete four modules of training, which together form the Army Reserve Commissioning Course. For professionally qualified officers (doctors, vets, lawyers etc.), there is only one stage at the AOSB. Module A consists of basic field training and elementary military skills. This can be completed at either a UOTC over a number of weekends or over 2 weeks at the Royal Military Academy Sandhurst (RMAS). Module B covers training in Tactics, Leadership, Doctrine and Navigation, both in theory and in practice, with a focus on the section battle drills and the platoon combat estimate. This training can either be spread over 10 weekends at a UOTC, or 2 weeks at the RMAS. Module C builds on the Tactics, Leadership, Doctrine, and Navigation taught in Module B, with a greater focus on the theory behind these constructs. CBRN training is also added at this point, and Officer Cadets undergo a number of field exercises to test their military and leadership skills. Module C can only be undertaken at the RMAS. Module D Once the Officer Cadet has completed their Army Officer Selection Board, they can complete this final module, after which they will become commissioned officers in the British Army. Based at the RMAS, this module consists primarily of a prolonged field exercise, followed by drill training in preparation for the passing out parade.
Vitamin A deficiency is common in developing countries but rarely seen in developed countries. Approximately 250,000 to 500,000 malnourished children in the developing world go blind each year from a deficiency of vitamin A. Vitamin A deficiency in expecting mothers increases the mortality rate of children shortly after childbirth. Night blindness is one of the first signs of vitamin A deficiency. Vitamin A deficiency contributes to blindness by depleting the necessary form needed for rhodopsin.
Sources: en.wikipedia.org
The oxides and peroxides for these alkali metals do exist, but do not form upon direct reaction of the metal with oxygen at standard conditions. In addition, the small size of the Li+ and O2− ions contributes to their forming a stable ionic lattice structure. Under controlled conditions, however, all the alkali metals, with the exception of francium, are known to form their oxides, peroxides, and superoxides. The alkali metal peroxides and superoxides are powerful oxidising agents. Sodium peroxide and potassium superoxide react with carbon dioxide to form the alkali metal carbonate and oxygen gas, which allows them to be used in submarine air purifiers; the presence of water vapour, naturally present in breath, makes the removal of carbon dioxide by potassium superoxide even more efficient. All the stable alkali metals except lithium can form red ozonides (MO3) through low-temperature reaction of the powdered anhydrous hydroxide with ozone: the ozonides may be then extracted using liquid ammonia. They slowly decompose at standard conditions to the superoxides and oxygen, and hydrolyse immediately to the hydroxides when in contact with water. Potassium, rubidium, and caesium also form sesquioxides M2O3, which may be better considered peroxide disuperoxides, [(M+)4(O2−2)(O−2)2]. Rubidium and caesium can form a great variety of suboxides with the metals in formal oxidation states below +1.
=== Research conducted === In 1963, Nikolai Kardashev and Gennady Borissovich Sholomitskii studied the CTA 102 radio source on the 920 MHz band from the Crimea Deep Space Station, looking for signs of a Type III civilization. CTA 102 had been discovered by Sholomitskii a year earlier, and Kardashev quickly saw it as a possible artificial source to study in order to validate his classification. The observation lasted until February 1965, and on April 12, Sholomitskii announced to the press (via the Russian ITAR-TASS) that Soviet astronomers had discovered a signal that could be of extraterrestrial origin. On April 14, he gave a conference in Moscow where he repeated his announcement; but by November 1964, two American astronomers had identified CTA 102 as a quasar, and their publication definitively closed the "CTA 102 case". It was the study of this source that had led to the Byurakan conference in 1964. In 1975 and 1976, the American astronomers Frank Drake and Carl Sagan searched at Arecibo for signs of Type II civilizations in four galaxies of the Local Group: M33, M49, Leo I and Leo II. The year before, the two men had sent mankind's first message to M13. The results were published as "The Search for Extraterrestrial Intelligence" in Scientific American in May 1975. In 1976, Kardashev, Troitskii, and Gindilis used the RATAN-600 radio telescope in the North Caucasus to search for signals from Type II or III civilizations in the Milky Way and other nearby galaxies.
For light microscopy, paraffin wax is the most frequently used embedding material. Paraffin is immiscible with water, the main constituent of biological tissue, so it must first be removed in a series of dehydration steps. Samples are transferred through a series of progressively more concentrated ethanol baths, up to 100% ethanol to remove remaining traces of water. Dehydration is followed by a clearing agent (typically xylene although other environmental safe substitutes are in use) which removes the alcohol and is miscible with the wax, finally melted paraffin wax is added to replace the xylene and infiltrate the tissue. In most histology, or histopathology laboratories the dehydration, clearing, and wax infiltration are carried out in tissue processors which automate this process. Once infiltrated in paraffin, tissues are oriented in molds which are filled with wax; once positioned, the wax is cooled, solidifying the block and tissue.
Penile ultrasonography with doppler can be used to examine the erect penis. Most cases of ED of organic causes are related to changes in blood flow in the corpora cavernosa, represented by occlusive artery disease (in which less blood is allowed to enter the penis), most often of atherosclerotic origin, or due to failure of the veno-occlusive mechanism (in which too much blood circulates back out of the penis). Before the Doppler sonogram, the penis should be examined in B mode, in order to identify possible tumors, fibrotic plaques, calcifications, or hematomas, and to evaluate the appearance of the cavernous arteries, which can be tortuous or atheromatous. Erection can be induced by injecting 10–20 μg of prostaglandin E1, with evaluations of the arterial flow every five minutes for 25–30 min (see image). The use of prostaglandin E1 is contraindicated in patients with predisposition to priapism (e.g., those with sickle cell anemia), anatomical deformity of the penis, or penile implants. Phentolamine (2 mg) is often added. Visual and tactile stimulation produces better results. Some authors recommend the use of sildenafil by mouth to replace the injectable drugs in cases of contraindications, although the efficacy of such medication is controversial. Before the injection of the chosen drug, the flow pattern is monophasic, with low systolic velocities and an absence of diastolic flow. After injection, systolic and diastolic peak velocities should increase, decreasing progressively with vein occlusion and becoming negative when the penis becomes rigid (see image below).
=== In English translation === Kermani, Navid (2011). The Terror of God: Attar, Job and the Metaphysical Revolt. Translated by Wieland Hoban. Cambridge, UK: Polity. ISBN 978-0-7456-4527-8. OCLC 668946700. Kermani, Navid (2015). God is Beautiful: The Aesthetic Experience of the Quran. Translated by Tony Crawford. Cambridge, UK: Polity Press. ISBN 978-0745651675. OCLC 881418248. Kermani, Navid (2016). Between Quran and Kafka: West-eastern Affinities. Translated by Tony Crawford. Cambridge, UK: Polity Press. ISBN 978-1-5095-0033-8. OCLC 940342167. Kermani, Navid (2017). Upheaval: The Refugee Trek through Europe. Translated by Tony Crawford. Cambridge, UK: Polity Press. ISBN 978-1-5095-1868-5. OCLC 982184554. Kermani, Navid (2017). Wonder Beyond Belief: On Christianity. Translated by Tony Crawford (English ed.). Cambridge, UK: Polity Press. ISBN 978-1509514847. (2018 Schlegel-Tieck Prize.) Kermani, Navid (2018). State of Emergency: Travels in a Troubled World. Translated by Tony Crawford. Cambridge, UK: Polity. ISBN 978-1-5095-1470-0. Kermani, Navid (2019). Love Writ Large. Translated by Alexander Booth. London: Seagull Books. ISBN 978-0-85742-602-4. OCLC 1051682987. Kermani, Navid (2020). Along the Trenches: A Journey through Eastern Europe to Isfahan. Translated by Tony Crawford. Cambridge, UK: Polity Press. ISBN 978-1-5095-3557-6. OCLC 1097364913. Kermani, Navid (2022). Tomorrow Is Here: Speeches. Translated by Tony Crawford. Cambridge, UK: Polity Press. ISBN 978-1-5095-5056-2. OCLC 1292971292. Kermani, Navid (2023).
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
Peptide mapping with tandem mass spectrometry is the standard approach. The peptide is digested with an enzyme such as trypsin, and the resulting fragments are matched against the expected sequence.